PubMed HealthSearch

PubMed · 6405573

Thyroid function in goitrous subjects with thyroxine binding globulin deficiency.

Abstract

The co-existence of thyroxine binding globulin (TBG) deficiency and euthyroid goitre in the same family raised the possibility that the disorders might be related. However, although both disorders co-existed in some members of the family, other members had either but not both conditions. These observations exclude the possibility that goitre development was solely due to alterations in thyroid activity brought about by TBG deficiency. It is possible, however, that the defect in protein binding might have enhanced goitre development in predisposed individuals as the two largest goitres occurred in TBG deficient subjects. Of the conventional parameters used to assess thyroid hormone levels in TBG deficient subjects, only the free triiodothyronine index consistently reflected the euthyroid status of these patients as established by clinical examination and TSH levels.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F P Callan, M J Duffy, G J Duffy, R J Farrell, T J McKenna. 1983. Thyroid function in goitrous subjects with thyroxine binding globulin deficiency.. https://doi.org/10.1530/acta.0.1020527

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies